Affinity Asset Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Affinity Asset Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-170,000	Closed	-$3.68M	–	84
2022 Q3	$3.68M	Buy	170,000 +100,000	+143%	+$2.73M	1.03%	29
2022 Q2	$1.97M	Sell	70,000 -137,500	-66%	-$3.64M	0.83%	31
2022 Q1	$9.57M	Buy	207,500 +90,000	+77%	+$4.85M	1.53%	11
2021 Q4	$9.88M	Buy	117,500 +40,000	+52%	+$3.1M	3.59%	6
2021 Q3	$5.17M	Sell	77,500 -64,918	-46%	-$3.74M	1.3%	18
2021 Q2	$7.58M	Buy	142,418 +64,918	+84%	+$3.48M	2.71%	10
2021 Q1	$3.36M	Buy	+77,500	New	+$3.34M	1.14%	22

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Affinity Asset Advisors's ZNTL Position: Q4 2022 in Review

Affinity Asset Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 170,000 shares — an estimated $3.68M sold.

Affinity Asset Advisors first reported a position in ZNTL in Q1 2021 and held it in 7 quarters. The position peaked at $9.88M in Q4 2021. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

Affinity Asset Advisors reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Affinity Asset Advisors sold 170,000 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $3.68M.
Affinity Asset Advisors first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 7 quarters.
Affinity Asset Advisors's Zentalis Pharmaceuticals position peaked at $9.88M in Q4 2021.
106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.